Literature DB >> 22937860

Surgical approaches for resection of vestibular schwannomas: translabyrinthine, retrosigmoid, and middle fossa approaches.

Roukoz Chamoun1, Joel MacDonald, Clough Shelton, William T Couldwell.   

Abstract

Surgical removal remains one of the key treatment modalities for vestibular schwannomas. A team approach between a neurotologist and a neurosurgeon offers the patient the expertise of both specialties and maximizes the chances for an optimal outcome. Vestibular schwannomas can typically be resected through 1 of 3 main surgical approaches: the translabyrinthine, the retrosigmoid, or the middle fossa approaches. In this report and videos, the authors describe and illustrate the indications and surgical techniques for the removal of these tumors.

Entities:  

Mesh:

Year:  2012        PMID: 22937860     DOI: 10.3171/2012.6.FOCUS12190

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  15 in total

1.  Role of squamosal suture as a consistent landmark for middle fossa approach craniotomy: an anatomical study.

Authors:  Kenan Alkhalili; Mohammed Tantawy; Mohab M Nageeb; Mohamed A Ragaee; Gasser H Alshyal; Dunbar S Alcindor; Douglas A Chen; Khaled M Abdel Aziz
Journal:  J Neurol Surg B Skull Base       Date:  2014-09-13

2.  Three-dimensional Anatomical Analysis of Surgical Landmarks for the Middle Cranial Fossa Approach.

Authors:  Bong Jin Choi; Min Ju Kim; Ki-Hong Chang; Sang Won Yeo; Beom Cho Jun
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-04-09

3.  Functional Outcomes and Postoperative Cerebral Venous Sinus Thrombosis after Translabyrinthine Approach for Vestibular Schwannoma Resection: A Radiographic Demonstration of Anatomic Predictors.

Authors:  Christina Gerges; Patrick Malloy; Nicholas Rabah; Dana Defta; Yifei Duan; Christina H Wright; Marte van Keulen; James Wright; Sarah Mowry; Cliff A Megerian; Nicholas Bambakidis
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-04

Review 4.  Audiovestibular symptoms and facial nerve function comparing microsurgery versus SRS for vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Vinod Kumar Yakkala; Marco Mammi; Nayan Lamba; Renuka Kandikatla; Bhaskar Paliwal; Hoda Elshibiny; C Eduardo Corrales; Timothy R Smith; Rania A Mekary
Journal:  Acta Neurochir (Wien)       Date:  2022-08-13       Impact factor: 2.816

Review 5.  Assessing the long-term safety and efficacy of gamma knife and linear accelerator radiosurgery for vestibular schwannoma: A systematic review and meta-analysis.

Authors:  Sergio W Guadix; Alice J Tao; Anjile An; Michelle Demetres; Umberto Tosi; Swathi Chidambaram; Jonathan P S Knisely; Rohan Ramakrishna; Susan C Pannullo
Journal:  Neurooncol Pract       Date:  2021-08-13

6.  Management of CSF leakage after microsurgery for vestibular schwannoma via the middle cranial fossa approach.

Authors:  Matthias Scheich; Christian Ginzkey; Desiree Ehrmann-Müller; Wafaa Shehata-Dieler; Rudolf Hagen
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-09       Impact factor: 2.503

7.  Multifactor Influences of Shared Decision-Making in Acoustic Neuroma Treatment.

Authors:  Jason C Nellis; Jeff D Sharon; Seth E Pross; Lisa E Ishii; Masaru Ishii; Jacob K Dey; Howard W Francis
Journal:  Otol Neurotol       Date:  2017-03       Impact factor: 2.311

8.  Facial and Cochlear Nerve Complications following Microsurgical Resection of Vestibular Schwannomas in a Series of 221 Cases.

Authors:  Jun Zhang; Bai-Nan Xu; Yuan-Zheng Hou; Guo-Chen Sun; Yan Jiang
Journal:  Med Sci Monit       Date:  2015-06-09

9.  Translabyrinthine approach to internal auditory meatus: A retrospective study.

Authors:  Sunil Goyal; Kiran Natarajan; Amarnath Devarasetty; T Sarankumar; Neha Chauhan; Mohan Kameswaran
Journal:  Med J Armed Forces India       Date:  2017-01-04

Review 10.  Hearing Restoration in Neurofibromatosis Type II Patients.

Authors:  Jeon Mi Lee; Jin Woo Chang; Jae Young Choi; Won Seok Chang; In Seok Moon
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.